Tonix Pharmaceuticals

The first known case in the U.S. of clade I #mpox was confirmed in California according to the Centers for Disease Control and Prevention: https://bit.ly/3AZAbLV and https://bit.ly/48RYFU1 Tonix Pharmaceuticals is developing TNX-801 as a new, single-dose #mpox and #smallpox vaccine candidate that targets clade I and clade II #mpox and has shown to protect animals from lethal clade I #mpox challenge after a single dose: https://bit.ly/3ZkqAI3 Clade Ib #mpox is the cause of a global #mpox public health emergency that was declared by World Health Organization (WHO) in August 2024 and infects adults and children: https://bit.ly/40RqoSR This clade Ib #mpox is different from the clade IIb #mpox that caused the global outbreak in 2022 and is still circulating in the U.S. after infecting about 30,000 here, mostly gay men. Learn more about recent tolerability data of Tonix Pharmaceuticals's TNX-801 published in mSphere Journal here https://bit.ly/3ZjlvAV and here https://bit.ly/4eFdHh6

Tonix Pharmaceuticals to present at the 2024 Virtual Investor Summit on Thursday, November 21 at 10 a.m. ET. Read more here: https://bit.ly/40SoG3u Attendees can watch the live webcast here: https://bit.ly/3CwRww5

Tonix Pharmaceuticals presented data and analyses of TNX-102 SL treatment effects on fibromyalgia at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting, hosted by American College of Rheumatology. Learn more here: https://bit.ly/4eyDlEf

Tonix Pharmaceuticals announces peer-reviewed publication in mSphere Journal highlighting the tolerability of TNX-801, Tonix’s single-dose #mpox and smallpox vaccine candidate, in immune-compromised animals. Learn more here: https://bit.ly/3AJKMKS

Tonix Pharmaceuticals announces poster presentation on TNX-102 SL for fibromyalgia at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting on Sunday, November 17 at 10:30 a.m. ET in Washington, D.C., hosted by American College of Rheumatology.?Learn more here: https://bit.ly/48R7EF9

Tonix Pharmaceuticals reports third quarter 2024 financial results and operational highlights. Read more here: https://bit.ly/4hYXFBM

Tonix Pharmaceuticals announces research agreement with Kenya Medical Research Institute (KEMRI) to design, plan and seek regulatory approval for a Phase I clinical study of TNX-801 for #mpox in Kenya. Read more here: https://bit.ly/4evv4kq

Tonix Pharmaceuticals presented preclinical data on potential #mpox vaccine candidate TNX-801 at World Vaccine Congress-Europe 2024, including positive tolerability data in animal models. Learn more here: https://bit.ly/3NVM3kV

Tonix Pharmaceuticals announces presentation by Seth Lederman, M.D., CEO of Tonix, at BIO-Europe? 2024 on Monday, November 4, 2024, at 1:00 p.m. CET. The conference is being held November 4-6, 2024, in Stockholm, Sweden. Learn more here:?https://bit.ly/3C0PGnh

Tonix Pharmaceuticals will present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024, at 9:30 a.m. ET, at the Mandarin Oriental in New York City. The company will also host investor meetings. Read more here: https://bit.ly/48p4I2k